Best Lisocabtagene Maraleucel (Breyanzi) Medicine in India

Lisocabtagene Maraleucel (Breyanzi) is a personalized CAR T-cell therapy used to treat certain types of relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in eligible adults. It uses genetically modified T cells to recognize and attack cancer cells, helping the immune system destroy abnormal B cells and control disease progression.

Lisocabtagene Maraleucel (Breyanzi) is administered as a single intravenous infusion by a qualified healthcare professional after the patient's T cells have been collected, modified, and prepared for treatment. Lymphodepleting chemotherapy is generally given before the infusion. Close medical monitoring is required after treatment to detect and manage serious reactions.

Common side effects of Lisocabtagene Maraleucel (Breyanzi) may include cytokine release syndrome, fatigue, fever, headache, low blood cell counts, nausea, diarrhea, swelling, and infections. Serious side effects may include cytokine release syndrome and neurologic toxicities. Inform your doctor immediately if you develop fever, chills, confusion, difficulty speaking, severe weakness, breathing difficulties, or other concerning symptoms.

Treatment of Relapsed or Refractory B-Cell Cancers

Lisocabtagene Maraleucel (Breyanzi) is used to treat certain relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in eligible adults. It uses genetically modified T cells to recognize and attack abnormal B cells, helping to reduce cancer-cell growth and control disease progression.

Some side effects of Lisocabtagene Maraleucel (Breyanzi) may improve as the body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Lisocabtagene Maraleucel (Breyanzi)

Lisocabtagene Maraleucel (Breyanzi) is given as a single intravenous infusion by a qualified healthcare professional. Before treatment, the patient's T cells are collected and genetically modified to recognize cancer cells. Lymphodepleting chemotherapy is usually given before the infusion. Close monitoring is required after treatment to identify and manage cytokine release syndrome and neurological reactions.

Lisocabtagene Maraleucel (Breyanzi) is a CD19-directed CAR T-cell therapy. The patient's T cells are genetically modified to produce a chimeric antigen receptor (CAR) that recognizes CD19, a protein found on many B cells and B-cell cancer cells. These modified T cells bind to CD19-positive cancer cells and activate an immune response that helps destroy them.

AlcoholCONSULT YOUR DOCTOR

Avoid alcohol during treatment and recovery, as it may worsen dizziness, fatigue, or other side effects. Follow your doctor's advice.

PregnancyCONSULT YOUR DOCTOR

Lisocabtagene Maraleucel may pose risks to an unborn baby. Women who can become pregnant should discuss effective contraception with their doctor before and after treatment.

BreastfeedingCONSULT YOUR DOCTOR

Do not breastfeed during treatment unless your doctor advises otherwise, as the effects on a breastfed child are not fully known.

DrivingCONSULT YOUR DOCTOR

Do not drive or operate machinery until your doctor confirms it is safe, as treatment may cause dizziness, confusion, or neurological effects.

KidneyCAUTION

Inform your doctor if you have kidney problems. Your healthcare team may monitor kidney function and provide appropriate medical care.

LiverCAUTION

Tell your doctor about any liver condition. Liver function may be monitored during treatment, and report yellowing of the skin or eyes, dark urine, or unusual tiredness promptly.